The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | Breast cancer: new advances in personalized medicine and therapeutics
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches upon personalized medicine and how it is helping to determine the best course of treatment, before discussing new data from trials including TAILORx (NCT00310180) and PERSEPHONE (ISRCTN52968807). Dr Burris mentions the limitations currently posed by these new therapies, before concluding his interview by briefly mentioning the use of pembrolizumab and combination therapy in the treatment of non-small cell lung cancer. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
